India caps trade margins on anti-cancer drugs at 30%. India has capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing prices by up to 70%, per the Indian Pharmaceutical Alliance. Experts from AIIMS Delhi welcomed the move, citing reduced financial burden on patients, while stressing the need for effective implementation, quality assurance, and uninterrupted medicine supply.